TAPIOCA: The frequency of T790M Alleles and their Prognostic sIgnificance during the follow-On treatment in EGFR M+ NSCLC patients who were treated with Afatinib and gefitinib

Not Applicable

Recruiting

• Conditions: Neoplasms

• Registration Number: KCT0008468
• Lead Sponsor: Asan Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1) Adult men and women over 19 years of age
2) Patients with EGFR mutation-positive advanced/metastatic non-small cell lung cancer who have been treated with afatinib or gefitinib for more than 6 months as first-line treatment
3) Patients with confirmed T790M mutation positive in tumor tissue or blood samples after failure of afatinib or gefitinib treatment as first-line treatment
4) Patients who received osimertinib as a second-line treatment after confirming acquired resistance T790M mutation
5) Patients with T790M allele frequency results obtained from tumor tissue or blood samples after afatinib or gefitinib treatment as the first treatment

Exclusion Criteria

1) Patients unable to review medical records
2) Patients with brain metastases Patients with brain metastases

Study & Design

• Study Type: Observational Study
• Study Design: Not specified